Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.

Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD.

Liver Transpl. 2009 Jul;15(7):782-9. doi: 10.1002/lt.21760.

2.

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.

Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS.

Liver Transpl. 2007 Aug;13(8):1100-8.

3.

Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.

Raziorrouh B, Jung MC, Schirren CA, Loehe F, Thiel M, Nitschko H, Diepolder H, Ulsenheimer A, Heeg M, Zachoval R, Gruener NH.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):778-83. doi: 10.1097/MEG.0b013e3282f762f8.

PMID:
18617783
4.

Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.

Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, Risalde B, Rubin A, Cañada R, Palau A, Rayón JM.

Liver Transpl. 2009 Jul;15(7):738-46. doi: 10.1002/lt.21707.

5.

Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.

Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D.

Liver Transpl. 2008 Dec;14(12):1766-77. doi: 10.1002/lt.21635.

6.

Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.

Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, Fernández-Aguilar JL, Suárez Muñoz MA, González-Sánchez AJ, Pérez Daga JA, Ramírez Plaza CP, Carrasco Campos J, Jiménez Mazure C, Becerra Ortíz R.

Transplant Proc. 2008 Nov;40(9):2994-6. doi: 10.1016/j.transproceed.2008.08.116.

PMID:
19010171
7.

Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.

Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, Meneu JC, Lumbreras C, Solís-Herruzo JA, Moreno E.

Liver Transpl. 2009 Aug;15(8):948-55. doi: 10.1002/lt.21780.

8.

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.

Aguilera V, Berenguer M, Rubín A, San-Juan F, Rayón JM, Prieto M, Mir J.

Liver Transpl. 2009 Jan;15(1):79-87. doi: 10.1002/lt.21626.

9.

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayón JM, Berenguer J.

Liver Transpl. 2006 Jul;12(7):1067-76.

10.

A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.

Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C, Menichetti F, Brunetto MR, Scatena F, Filipponi F.

Transplantation. 2008 Dec 27;86(12):1666-71. doi: 10.1097/TP.0b013e31818fe505.

PMID:
19104402
11.

Management of recurrent hepatitis C after liver transplantation.

Teixeira R, Papatheodoridis GV, Burroughs AK.

J Viral Hepat. 2001 May;8(3):159-68. Review.

PMID:
11380792
12.

A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.

Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A.

Transpl Int. 2005 Dec;18(12):1336-45.

13.

Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.

Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F.

Dig Liver Dis. 2009 May;41(5):350-6. doi: 10.1016/j.dld.2008.09.018. Epub 2008 Nov 28.

PMID:
19046932
16.
17.

The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.

Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR.

Transplantation. 2012 Jul 27;94(2):197-203. doi: 10.1097/TP.0b013e3182547551.

PMID:
22766768
18.

Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.

Petta S, Cammà C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G, Craxì A.

Antivir Ther. 2009;14(5):631-9.

PMID:
19704165
19.

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR.

Liver Transpl. 2006 Jan;12(1):51-7.

20.

A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C.

Chang ML, Sung KF, Sheen IS, Lin SM, Yeh CT.

J Viral Hepat. 2009 May;16(5):359-66. doi: 10.1111/j.1365-2893.2009.01090.x. Epub 2009 Feb 20.

PMID:
19243501

Supplemental Content

Support Center